TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Cyclobenzaprine for Treatment of Sleep Disturbance in Aromatase Inhibitor-treated Breast Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female gender, age ≥ 18, postmenopausal.~* Histologically proven stage 0-III invasive carcinoma of the breast~* Initiating or have been receiving a standard dose of aromatase inhibitor therapy (letrozole 2.5mg once daily or exemestane 25mg once daily or anastrozole 1mg once daily) for up to a total of 48 months of AI therapy.~* Trouble sleeping during the past week. (After signing the informed consent document, subjects must also have a global PSQI score of ≥5)~* ECOG performance status 0-2 (see Appendix A).~Exclusion Criteria:~* Known hypersensitivity to cyclobenzaprine or any of the inactive ingredients~* Diagnosis of sleep apnea that is currently interfering with sleep or requiring CPAP, restless leg syndrome that is currently interfering with sleep or requiring medication, or Epworth sleepiness scale \>10.~* Subjects with a history of hypothyroidism must have been on a stable dose of thyroid replacement medicine for at least 3 months prior to enrollment~* Treatment with steroids within 1 month~* Treatment with monoamine oxidase inhibitors (MAO-I) within 14 days of enrollment.~* Concurrent treatment with bupropion, MAO inhibitors, phenothiazines (including thioridazine), selegiline, tramadol, or medications known to prolong the QT interval (www.azcert.org/medical-pros/drug-lists/drug-lists.cfm)~* Currently primary psychiatric diagnosis (schizophrenia, psychosis) or suicidal ideation, history of bipolar disorder, or seizure disorder~* Known moderate or severe hepatic impairment~* History of congestive heart failure or cardiac arrhythmia (other than atrial fibrillation); myocardial infarction within the past 6 months~* Uncontrolled narrow-angle glaucoma~* Pregnant or breast feeding~* Serious or unstable medical condition that could likely lead to hospitalization during the course of the study or compromise study participation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyclobenzaprine (Type: EXPERIMENTAL): Cyclobenzaprine (Flexeril) 5 milligrams orally 2 hours before bed, for a total of 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Whole Food Intervention on Mucositis in Patients Treated for Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histopathologically confirmed diagnosis of head \& neck carcinoma~* Scheduled to undergo continuous daily course of radiation therapy with or without chemotherapy~* No other serious concurrent medical illness as determined by the Principle Investigator~* Absolute neutrophil count ≥ 500/mm3~* Platelet count ≥ 50,000/mm3~* No history of insulin-dependent diabetes mellitus~* No prior hypersensitivity reaction to compound components~Exclusion Criteria:~* Dislike of the available forms of the WFI~* Allergy or food intolerance relevant to the ingredients~* Lack of access to refrigerated storage for the WFI~* Inability or unwillingness to participate twice a week~* Inability to swallow~* Undergoing treatment for HIV with HIV medications~* Ongoing alcohol and/or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Whole Food Intervention Treated (Type: EXPERIMENTAL): Group of participants given the experimental WFI along with standard cancer treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes mellitus for at least 5 years~* Candidate for islet cell transplantation based upon local accepted practice and guidelines~* Reduced awareness of hypoglycaemia~Exclusion Criteria:~* Treatment with any anti-diabetic medication other than insulin including insulin pump within 4 weeks of trial start~* Any previous organ transplantation~* A history of acute idiopathic or chronic pancreatitis~* Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): None
- Liraglutide placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women at least 19 years of age~* Patients with stable coronary artery disease who were successfully treated with zotarolimus-eluting stents~* Patients without major bleeding or MACE (myocardial infarction, stent thrombosis, stoke, repeat revascularization) within 6 months after zotarolimus-eluting stent placement~* The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.~Exclusion Criteria:~* Persistent thrombocytopenia (platelet count \<100,000/µl)~* A known intolerance to a study drug (aspirin, clopidogrel)~* Patients requiring long-term oral anticoagulants or cilostazol~* Patients presented with acute myocardial infarction (STEMI or NSTEMI) at the time of index procedure~* Planned cardiac surgery (e.g., CABG, valve repair or replacement, or aneurysmectomy) or planned major non-cardiac surgery within 18 months after procedure~* Bare-metal stent implantation at the time of index procedure~* Chronic disease requiring treatment with oral, intravenous, or intra-articular corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible).~* A diagnosis of cancer in the past 2 years or current treatment for the active cancer.~* Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.~* Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST \> 3 times upper limit of normal).~* History of adult asthma manifested by bronchospasm in the past 6 months, or currently taking regular anti-asthmatic medication(s).~* Unwillingness or inability to comply with the procedures described in this protocol.~* Patients pregnant or breast-feeding or child-bearing potential.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Short term dual therapy (Type: EXPERIMENTAL): None
- Long term dual therapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Community Acquired Sepsis Cohort

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient older than 18 years old~* Patient hospitalized during the study period for community infectious diseases at the CHU of Rennes~Exclusion Criteria:~* Written objection from the patient to the computer processing of his data~* Pregnant women~* Persons subject to major legal protection (safeguarding justice, guardianship, trusteeship), persons deprived of liberty

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Ponatinib for Squamous Cell Lung and Head and Neck Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Measurable disease~* Documented evidence of disease progression following most recent therapy~* Estimated life expectancy greater than 12 weeks~Exclusion Criteria:~* Pregnant or breastfeeding~* Prior chemotherapy or brain radiotherapy within 4 weeks of entering study~* Receiving other investigational agents~* Untreated or progressive brain metastases~* Prior treatment with or allergic reactions attributed to compounds of similar chemical or biologic composition to ponatinib~* Known HIV positive on combination antiretroviral therapy~* Clinically uncontrolled hypertension~* Previous or concurrent malignancy except adequately treated basal or squamous cell skin cancer, in situ carcinoma of the cervix, or other solid tumor treated curatively and without evidence of recurrence for at least 5 years~* Active or uncontrolled clinically significant infection~* Chronic GI disease that may affect bioavailability of ponatinib~* History of significant bleeding disorder unrelated to cancer~* Uncontrolled intercurrent illness~* Clinically significant ventricular arrythmia~* History of chronic pancreatitis, alcohol abuse or uncontrolled hypertriglyceridemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ponatinib Treatment Arm (Type: EXPERIMENTAL): Ponatinib taken by mouth daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects from both sexes aged between 18 and 65 years;~* Patient diagnosed with mild depression episode confirmed by psychiatric and psychometric evaluation, presenting basal scores above 08 and below 24 measured by the Hamilton Rating Scale (HAM-D);~* Capable of understanding the nature and objective of the study, including risks and adverse effects and intended to cooperate with the researcher and act in accordance with the requirements of the entire protocol, which comes to be confirmed by signing the informed consent.~Exclusion Criteria:~* Have a known hypersensitivity to Trichilia catigua or history of serious adverse reactions;~* Shows risk of suicide, assault, murder or moral exposure;~* Clinical history of bleeding disorders;~* Drug addiction, including alcohol;~* Known or suspected neoplasia;~* Knowledge positive test result for the human immunodeficiency virus;~* Patient not willing to adhere to the procedures of the Protocol;~* For women, can not be pregnant or nursing and must be in use of a contraception method during the participation in the study;~* Patients using other drugs with sedative or antidepressant action, which can not be suspended for 15 days (wash out);~* Diabetics;~* Hyperthyroidism;~* Participation in any experimental study or use of any experimental drug three months before the start of this study;~* Has any condition which the investigator deems relevant to the non-participation of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Escitalopram + LABCAT TCJUSS (Type: EXPERIMENTAL): Escitalopram 10mg + LABCAT TCJUSS 1000 mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night);
- Escitalopram + LABCAT TCJUSS placebo (Type: PLACEBO_COMPARATOR): Escitalopram 10mg + LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
- Escitalopram Placebo + LABCAT TCJUSS (Type: EXPERIMENTAL): Escitalopram Placebo + LABCAT TCJUSS 1000 mg daily (2 capsules in the morning + 2 capsules at night).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Evaluation of Late Rectal Injury Following CyberKnife Radiosurgery for Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed adenocarcinoma of the prostate (Biopsy within one year of enrollment)~* Signed Study-Specific Consent~* PSA within 60 days of registration~* Baseline American Urological Association (AUA)/ International Prognostic Scoring System (IPSS) score of \< 20~* Candidate for screening colonoscopy~* Pretreatment Colonoscopy/lower endoscopy done~Exclusion Criteria:~* Prior pelvic radiotherapy~* Prior radical prostate surgery~* Recent (within 5 years) or concurrent cancers other than non-melanoma skin cancer~* Implanted hardware adjacent to the prostate that would prohibit appropriate treatment planning and/or treatment delivery~* Inflammatory bowel disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CyberKnife Radiosurgery, Colonoscopy (Type: OTHER): CyberKnife radiosurgery for prostate cancer; bowel toxicity will be evaluated at 2 years by colonoscopy (lower endoscopy).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Female subjects, aged \<40yr at the time of breast cancer diagnosis~2. Diagnosis of operable breast cancer any T and N, any ER~3. Patients candidate to adjuvant chemotherapy for 4-8 cycles.~4. Patients compliant to adhere to all protocol procedures.~5. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 28 days prior to the start of the study treatment.~6. Negative pregnancy test at the study enrolment; fertile women must use effective contraception during chemotherapy~7. Patients must be able to understand and sign written informed consent.~   -~Exclusion Criteria:~1. Presence of distant metastasis~2. Clinically significant cardiovascular disease~3. Psychological or social conditions which might affect study compliance~4. Unstable neurologic function~5. Patients with known allergy to any of the components of the study medication~6. Pregnancy or lactation~7. Any condition that, in the opinion of the physician is likely to affect inclusion of the subject into the study.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Triptorelin (Type: EXPERIMENTAL): Triptorelin 3.75 administered every 28 days, for 4 to 7 injections depending on the number of cycles of chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Evaluation of Interscalene Nerve Catheters vs. Single Injection Blocks

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) physical status 1-3~* 18-79 years of age, inclusive~* body mass index of \< 36 kg/m2.~* The ability to understand local anesthetic related complications and care of a CPNB~* Presence of a caretaker with them during the first 24 hours of local anesthetic infusion, and on a daily basis.~* The ability to communicate with the practitioner managing the catheter.~* Residence within 2 hours of University of Wisconsin Hospital and Clinics~Exclusion Criteria:~* Any contraindication to a continuous interscalene catheter placement~* Clinically significant pulmonary disease~* Clinically significant cardiac disease~* Allergy to ropivacaine~* Peripheral or central nervous system disease~* Current (or planned) anticoagulation therapy or disease~* Local infection over area of catheter placement~* Renal or hepatic failure~* History of opioid dependence~* Significant psychiatric disease~* Pregnancy or lactation (Subjects will be asked if it is possible they could be pregnant. If a subject responds in the affirmative, a pregnancy test will be done.)~* Seizure Disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- interscalene block (Type: EXPERIMENTAL): interscalene block
- interscalene catheter (Type: EXPERIMENTAL): interscalene catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Labeled Glucose to Study Lymphocyte Replication and Survival in HIV-Infected Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~FOR PATIENTS:~18 years or older.~Able to provide informed consent and willing to comply with study requirements and clinic policies.~Negative urine pregnancy test (for women of childbearing potential).~Hemoglobin greater than 10 mg/dl.~Adequate venous access in the arms for blood drawing and 5 day infusions, and lymphapheresis~Willingness to allow stored samples to be used for future studies of HIV infection and/or immunological function, and willingness to have HLA typing performed. (For previously enrolled patients, patients would be requested, but not required, to provide permission to use stored samples in the future, and to permit HLA testing~FOR HIV POSITIVE PATIENTS:~Documented HIV infection (ELISA/Western blot positive or, for acute seroconverters, PCR positive).~FOR HIV NEGATIVE PATIENTS:~Negative ELISA/Western blot.~EXCLUSION CRITERIA:~Diabetes mellitus requiring drug therapy.~Active substance abuse or prior history of substance abuse which may interfere with protocol compliance.~Psychiatric illness or disturbance which, in the assessment of the protocol team, may affect patient safety or compliance.~Significant underlying cardiac, pulmonary, renal, gastrointestinal, rheumatologic or CNS disease as detectable on routine history, physical exam, or screening laboratory studies. Patients would be excluded if they had an acute or chronic underlying medical problem that in the judgment of the principal investigator could be exacerbated by participating in the protocol or that would make it difficult for them to comply with the protocol requirements.~Pregnancy or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- HIV-infected subjects (Type: EXPERIMENTAL): HIV-infected adults
- HIV-negative subjects (Type: EXPERIMENTAL): HIV-negative adults

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Risk Stratification in Primary Care Combined With Stratified-specific Physical Therapy Care for Low Back Pain

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. diagnosis of acute, chronic or non-specific LBP,~2. between 21 - 60 years of age,~3. able to stand and walk without assistance,~4. able to understand and read English,~5. able to understand and sign a consent form.~Exclusion Criteria:~1. active serious spinal complications such as tumor or infection,~2. active treatment for metastatic or bone cancer of the spine,~3. pregnancy or less than 6 months post-partum or less than 6 months post weaning.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Stratified Care (Type: EXPERIMENTAL): In three Participating Sites from Family Medicine sites, the Keele STarT Back Screening Tool will be administered to patients with acute and chronic low back pain and based on patients' responses, patients will be stratified into one of three risk groups: low, medium or high-risk. Patients in the medium- and high-risk groups will be referred to physical therapy for a matched physical therapy (PT) intervention based on the risk strata. Patients in the low-risk group will be managed in Family Medicine with an intervention that includes advice, reassurance, patient education, and NSAIDs (with no referral for imaging or specialist care).
- Current Care (Type: ACTIVE_COMPARATOR): In three Comparator Sites from Family Medicine, providers will give the current care at The University of Vermont Medical Center for patients with acute and chronic low back pain.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues